2023 Guidance and Q3 Earnings

Q3 2023 Total to adjusted profit reconciliation Total results Q3 2022 Q3 2023 Key commentary Operating profit Operating profit (£m) (£m) 1,191 1,949 Intangible amortisation 198 182 Intangible impairment 17 129 Major restructuring 73 110 Transaction-related 712 577 ViiV CCL¹ movements, primarily related to improved sales forecasts and FX2 Divestments, significant 414 legal and other (175) Receipt of dividend and distribution income from investments, including £184m fair value gain on Haleon investment Adjusted results 2,605 2,772 GSK Table may not sum due to rounding. See pages 19 and 20 of GSK's third quarter 2023 earnings release for a full reconciliation 1. Contingent consideration liabilities 2. Foreign exchange 31

View entire presentation